Latest news with #ADCs
Business Upturn
15 hours ago
- Business
- Business Upturn
Cohance Lifesciences appoints Yann D'Herve as CEO of CDMO Business
Cohance Lifesciences Ltd., a leading integrated Contract Development and Manufacturing Organization (CDMO), has announced the appointment of Yann D'Herve as the new Chief Executive Officer of its CDMO division, effective August 1, 2025. D'Herve brings over two decades of global leadership experience across pharmaceuticals, healthcare, and specialty chemicals. Known for his strategic vision and operational expertise, he has held multiple senior roles at Evonik, including Senior Vice President and General Manager of its Healthcare division. In that role, he oversaw 2,600 employees across nine manufacturing facilities and managed full P&L responsibilities, including CDMO operations. Advertisement Before that, D'Herve served as Vice President of Sales and Services at Evonik and held several leadership positions across manufacturing and commercial functions. He began his career on the shop floor, gaining valuable hands-on experience in production and operations. Cohance Lifesciences' CDMO platform offers end-to-end capabilities in small molecule APIs, Antibody Drug Conjugates (ADCs), and Nucleic Acid Chemistry, supporting global pharmaceutical innovators. D'Herve holds an MBA from Université de Picardie Jules Verne, Amiens, and a master's degree in chemistry from CPE Lyon, France. His appointment marks a strategic move by Cohance to strengthen its leadership and expand its innovation-led services for the global pharma industry.
Hindustan Times
3 days ago
- Health
- Hindustan Times
How India's biopharma industry is tackling the world's next health challenges
India has established itself as the pharmacy of the world. Supplying nearly 20% of the global generics market and 60% of the vaccine market, the country has established a strong foundation for affordable, large-scale pharmaceutical production. However, as global health challenges evolve, from infectious outbreaks to chronic lifestyle diseases, India's approach must also adapt. With non-communicable diseases like cardiovascular issues, diabetes, and others now making up over 70% of global deaths, the focus shifts from just volume to precision. If India wishes to maintain its global leadership and meet its ambitious goal of reaching a $300 billion biopharmaceutical industry by 2030, it must embrace next-generation therapies, such as gene therapies, antibody-drug conjugates (ADCs), and personalised medicine. Pharma(Pixabay/Representative) Fortunately, India, with its scientific talent, robust infrastructure, and exceptional population diversity, might be the launchpad the world needs. A significant milestone in India's biotech journey came in October 2023, when the CDSCO approved the country's first homegrown CAR-T cell therapy, NexCAR19. Developed entirely in India, this therapy for leukaemia and lymphoma showed response rates comparable to global CAR-T treatments. What sets it apart is the fact that it's being made available at a fraction of the typical price, making it a landmark in affordable, advanced immuno-oncology and India's first indigenously developed gene therapy. India is also making strides in antibody-drug conjugates (ADCs), that is, targeted cancer drugs that combine antibodies with potent toxins. Human trials for the first India-developed ADC candidate began in 2024. Meanwhile, the private sector is investing heavily in ADC manufacturing infrastructure. This comes at the right time: the global ADC market is expected to hit $23 billion by 2030, and India is positioning itself as a competitive, low-cost developer in this high-growth space. When it comes to precision medicine, India offers a uniquely rich landscape. With 1.4 billion people spanning diverse genetic, ethnic, and environmental backgrounds, it provides an ideal setting for testing and refining personalised therapies. The country also faces a dual burden of disease: persistent infectious threats like tuberculosis, accounting for 26–27% of global cases, alongside a rising tide of non-communicable diseases like diabetes and cardiovascular diseases. This diversity creates a robust, varied patient pool for clinical trials and real-world evidence studies. It's exactly what precision medicine needs: treatments that work not just in ideal conditions but in complex, real-world settings. Geographic and climatic variation, from the Himalayas to the coastal tropics, further adds to India's advantage. Significant strides in these arenas have been made possible due to active policy impetus. A cornerstone of India's biopharma push is the National Biopharma Mission, backed by ~$250 million from Indian and World Bank support. It enabled the country's first CAR-T trials and established a GMP-grade viral vector facility, fostering industry-academia collaboration and seeding a thriving biotech startup ecosystem. The government's ₹15,000 crore PLI scheme for the pharmaceutical industry is driving domestic production of complex biologics, vaccines, and high-value drugs. Covering 68 biopharma products and 157 priority drugs, it has approved 55 projects and already catalyzed over ₹30,600 crore in investment and ₹1.83 lakh crore in output by September 2024. The initiative aims to reduce India's import dependence and position the country as a global hub for advanced pharmaceutical manufacturing. The Ayushman Bharat Digital Mission is building a rich, anonymised health data backbone, enabling real-world evidence and post-market surveillance, and laying the foundation for precision medicine at a population scale. As DBT notes, India's genomic diversity is as varied as its culture or cuisine. Leveraging this scientifically will help address diseases that disproportionately affect Indian and developing-country populations. To this end, India is already scaling its genomic science to the population level. The Genome India Project has already sequenced 10,000 genomes from 83 ethno-linguistic groups and, as of January 2025, made this dataset publicly available. The government now targets 10 million genomes, supported by allied programs like CSIR's IndiGen and ICMR's National Genomics Core, which together are building reference variants for Indian populations. This genomic trove, paired with extensive patient registries, positions the country as a future hub for precision medicine and pharmacogenomics tailored to its uniquely diverse population. Despite strong momentum, India's biopharma industry must address a few critical roadblocks to realise its potential in advanced therapeutics fully. First, the regulatory framework needs to be strengthened. While CDSCO has deep experience with generics and vaccines, clear pathways for novel biologics, gene therapies, and precision medicine are still evolving. To this end, India must develop science-led, globally aligned regulatory guidelines with dedicated review pathways for advanced therapies, similar to the US FDA's breakthrough designation. Second, funding for innovation remains a bottleneck. Between 2013 and 2022, Indian biotech firms raised just $5 billion in venture capital, compared to $57 billion by U.S. biotech companies in 2023 alone. The government has tried to fill this gap through BIRAC grants and incubators and has recently proposed a Research-Linked Incentive (RLI) scheme to reward private R&D investments. Third, there is a talent shortage in high-end biopharma R&D and biomanufacturing. India's biopharma talent resilience score dropped from 6.3 in 2021 to 5.6 in 2023, and nearly half of pharma executives report difficulty hiring for critical roles. There is an immediate need to invest in specialised skill development programs for biologics, data science, and regulatory science to bridge this gap. Dr Tedros Adhanom Ghebreyesus, Director-General of the WHO, once said: 'Health is a human right. No one should get sick or die just because they are poor or because they cannot access the care they need.' India has the potential to turn that principle into practice by making the next generation of therapies not only practical but also accessible and affordable. If it succeeds, India won't just lead the biopharma race; it will redefine who gets to benefit from the future of medicine. This article is authored by Ankush Kapoor, co-founder and CEO, PharmNXT Biotech.
Yahoo
7 days ago
- Business
- Yahoo
Akari Therapeutics Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
Video webcast now available on-demand BOSTON and LONDON, July 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced Abizer Gaslightwala, Director, President and Chief Executive Officer of Akari, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. As part of the event, Mr. Gaslightwala dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast is now available on as well as the Presentations page in the Investors section of the Company's website ( About Akari Therapeutics Akari Therapeutics is an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs). The Company has developed its first novel payload, PH1, a spliceosome inhibitor designed to disrupt RNA splicing within cells. PH1 is highly differentiated in its mechanism of action against cancer cells from current ADC payloads that use Topoisomerase1 inhibitors or tubulin inhibitors. This splicing inhibition has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. Using this novel payload, Akari has the ability to generate multiple ADC molecules based on the desired application to a range of cancer targets of interest. Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers its novel PH1 payload directly into the tumor. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload. For more information about the Company, please visit and connect on X and LinkedIn. Investor Relations Contact JTC Team, LLC Jenene Thomas 908-824-0775 AKTX@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Standard
21-07-2025
- Business
- Business Standard
Anthem Biosciences jumps on debut
Shares of Anthem Biosciences were currently trading at Rs 726.35 at 10:21 IST on the BSE, representing a premium of 27.43% compared with the issue price of Rs 570. The scrip was listed at Rs 723.10, exhibiting a premium of 26.86% to the issue price. So far, the stock has hit a high of Rs 746.70 and a low of Rs 723.05. On the BSE, over 25.90 lakh shares of the company were traded in the counter so far. The initial public offer of Anthem Biosciences was subscribed 63.86 times. The issue opened for bidding on 14 July 2025 and it closed on 16 July 2025. The price band of the IPO is fixed between Rs 540 and 570 per share. The IPO is a full offer for sale of 5,95,61,404 equity shares at the upper price, amounting to Rs 3,395 crore. The company will not receive any funds from the offer; all proceeds will go to the selling shareholders based on the shares they offered. The promoters and promoter group hold a total of 43,17,47,949 equity shares, making up 76.87% of the pre-offer issued and paid-up equity share capital. Their shareholding after the IPO is expected to be around 74.69%. Anthem Biosciences is a tech-oriented CRDMO, providing drug discovery and manufacturing services, as well as specialty ingredients like probiotics, enzymes, and peptides. In FY25, CRDMO contributed 81.65% of its revenue. It serves over 550 clients in more than 44 countries, with Europe and North America being key markets. Supported by green chemistry and a partnership with Davos Pharma in the U.S., the company is growing its capacity and working on technologies like RNAi and ADCs. Ahead of the IPO, Anthem Biosciences on Friday, 11 July 2025, raised Rs 1,016.02 crore from anchor investors. The board allotted 1.78 crore shares at Rs 570 each to 60 anchor investors. The firm reported a consolidated net profit of Rs 451.26 crore and sales of Rs 1,844.55 crore for the twelve months ended on 31 March 2025.
Yahoo
18-07-2025
- Business
- Yahoo
ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing
Pharmaceutical companies and manufacturers, including MilliporeSigma (Burlington, US), Simtra BioPharma Solutions (Parsippany, US), Carbogen AMCIS (Bubendorf, Switzerland), and BioNTech (Mainz, Germany), have recently invested to meet growing demand for antibody drug conjugates (ADCs) as targeted cancer treatments. The global ADC market was $10bn in 2023 and is anticipated to exceed $58bn by 2030 (Figure 1). According to leading data and analytics company GlobalData, ADCs are expected to lead as the largest growing group of medicines in the innovation pipeline for 2025, as the industry has seen an increase in deals to develop and manufacture ADCs. Last week, MilliporeSigma and Simtra BioPharma Solutions announced a five-year partnership to offer ADC manufacturing services to pharmaceutical companies. MilliporeSigma will offer bioconjugation manufacturing at its ADC production facility in St. Louis, Missouri, US, while Simtra will offer drug product formulation and fill-finish services. Both companies will cover the analytical work for ADC production. MilliporeSigma has a history of prioritising ADC production - the company invested $76m into its St. Louis facility in 2024, in addition to the $65m spent five years ago to build its ADC active pharmaceutical ingredient (API) site in Madison, Wisconsin, US. Last year, Simtra announced a $14m investment to expand its ADC conjugation and purification capabilities. Earlier this month, Carbogen AMCIS, an API manufacturer, along with an unnamed Japanese partner, shared that they would invest $31m to prepare two facilities in Switzerland for the commercial production of linkers by the first quarter (Q1) and Q3 2027. Another Swiss contract development and manufacturing organisation (CDMO), Lonza (Basel, Switzerland), also revealed plans to increase its ADC production capabilities last year, with the addition of two manufacturing suites to its Visp, Switzerland, site. Last month, BioNTech announced that it was preparing to file for US Food and Drug Administration (FDA) approval in second-line endometrial cancer later this year for its next-gen human epidermal growth factor receptor 2-targeted ADC, BNT323. Currently, the company is 'reliant on a China-based CDMO' to supply BNT323. However, the company shared plans to diversify its supply chain and decrease dependence on its Chinese partner by adding multiple BNT323 'supply nodes'. With impending tariffs on pharmaceuticals under the current government, there has been a rise in deals and investment to grow US manufacturing operations. Combined with the surge of ADC demand for oncology indications, clinical and commercial manufacturing contracts for ADCs are anticipated to increase. Although only 6% of the current ADC landscape is made up of marketed drugs, the ADC addressable market is expected to grow over the next decade, with 268 drugs currently in clinical stages of development (Figure 2). "ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
